Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2022 16:05 ET | Source: Avadel Pharmaceuticals plc

Avadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

- Results identify mood, sleep and pain disorders as the most common comorbidities in people living with narcolepsy - - Encore presentations at ANA 2022 reinforce positive data from completed Phase...
September 22, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

DUBLIN, Ireland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
September 07, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

DUBLIN, Ireland, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
August 09, 2022 07:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially accelerate final approval and shorten launch...
August 02, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
July 19, 2022 07:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension

- Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate final approval DUBLIN, Ireland, July 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc...
June 29, 2022 16:05 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Corporate Update

Pursuing strategies to accelerate final approval of FT218 NDAOptimizing cost structure to fund strategic priorities and extend cash runwayContinuing key activities to accelerate launch timing of...
June 03, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum

DUBLIN, Ireland, June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
June 02, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference

DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
May 19, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel to Present Clinical Data for FT218 at SLEEP 2022

DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the...